Physician

Gregg C Newman, M.D.

According to 2025 Medicare claims, Gregg Newman, M.D. (NPI: 1275645053) practices hematology/oncology in the Santa Maria-Santa Barbara, CA market, with the plurality of this provider's patient population coming from Santa Barbara, CA. This provider's primary affiliated billing organization is SANSUM CLINIC (NPI: 1932121514; TIN: 956419205) and primary practice location at 93105-4230. Newman is affiliated with the Aledade A3299 CA MSSP Enhanced (ACO ID: A3299) and Caravan Collaborative Pathways (ACO ID: A4604), participating under the MSSP model.

Newman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 816 traditional Medicare patients, billed 243,049 HCPCS/CPT codes, and received $4,271,864 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,289 prescription claims across 257 beneficiaries totaling $6,936,409 in drug costs, led by Brukinsa (Zanubrutinib). DME data shows 37 claims. Open Payments data shows 51 records totaling $149,600. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,207,037 to $4,271,864. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,713,795 to $6,936,409. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	577	111,085	$1,207,037
2016	590	110,694	$1,729,571
2017	543	129,146	$1,814,830
2018	542	132,234	$2,026,485
2019	593	183,833	$2,947,699
2020	587	204,377	$3,396,440
2021	673	153,033	$2,747,188
2022	766	262,391	$4,328,565
2023	781	260,007	$3,908,883
2024	816	243,049	$4,271,864

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	201	1,289	$1,713,795
2016	217	1,442	$2,588,480
2017	189	1,299	$2,470,291
2018	192	1,031	$2,503,351
2019	191	1,095	$3,394,448
2020	165	809	$2,849,253
2021	191	861	$3,647,301
2022	225	1,225	$5,239,307
2023	231	1,203	$5,294,496
2024	257	1,289	$6,936,409

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	15	191	$66,976
2016	11	112	$42,324
2017	12	129	$27,008
2018	12	129	$12,272
2019	N/R	111	$9,824
2020	N/R	115	$6,369
2021	25	164	$9,321
2022	11	190	$9,641
2023	N/R	35	$6,542
2024	N/R	37	$889

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	133	475	$111
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	374	883	$102
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	139	151	$64
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	253	414	$12
96372	Injection of drug or substance under skin or into muscle	141	414	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Brukinsa	Zanubrutinib	58	1,740	$832,274
Xtandi	Enzalutamide	38	1,260	$599,246
Revlimid	Lenalidomide	28	784	$545,083
Pomalyst	Pomalidomide	23	623	$441,515
Jakafi	Ruxolitinib Phosphate	27	795	$433,384

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	18	$550
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	19	$339

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	39	$864	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	12	$148,736	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Gregg C. Newman, M.D.?

Tedicare shows public-source Medicare data for Gregg C. Newman, M.D. (NPI 1275645053), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Gregg C. Newman, M.D. have ACO affiliation data?

Gregg C. Newman, M.D. is shown with ACO affiliation data for Aledade A3299 CA MSSP Enhanced (MSSP, ACO ID A3299) and Caravan Collaborative Pathways (MSSP, ACO ID A4604).

What billing organization is linked to Gregg C. Newman, M.D.?

Gregg C. Newman, M.D. is linked to SANSUM CLINIC (billing NPI 1932121514) in the available physician profile data.

Does Gregg C. Newman, M.D. have Open Payments data?

Gregg C. Newman, M.D. has 51 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.